Add Row

Add Element

update

National Cannabis Newswire

update

Add Element

Home
Categories
- news
- trends
- insights
- industry
- legalization
- health
- culture
- advocacy
- Brands
- New Mexico Dispensaries
- Arizona Dispensaries

September 25.2025

2 Minutes Read

Hemp vs. Legal Cannabis: Who Will Come Out on Top?

Man discussing 'Hemp vs. Legal Cannabis', serious expression indoors

Understanding the Battle: Hemp vs. Legal Cannabis

The ongoing discussion surrounding hemp and legal cannabis has gained momentum as more states move towards legalization and acceptance of cannabis-derived products. What does this mean for consumers, businesses, and the market? In light of the recent video titled Hemp vs. Legal Cannabis: Who's winning? ?? Let's dive in!, we take a closer look at the implications of this evolving landscape.

In the video titled 'Hemp vs. Legal Cannabis: Who's winning? ?? Let's dive in!', the discussion dives into the evolving landscape of cannabis legality and its implications, fueling our analysis of this critical topic.

Legal Frameworks: A Complex Terrain

The distinction between hemp and cannabis often lies in their legal definitions. Hemp, often considered a low-THC counterpart of cannabis, is primarily used for industrial purposes, while legal cannabis focuses on higher THC content for recreational and medicinal use. Understanding these legal frameworks is crucial for consumers and businesses as they navigate production, sale, and usage within varying state laws.

The Market Dynamics: Who's Winning?

As of today, the hemp market has seen significant growth due to its various applications, including textiles, construction materials, and personal care products. In contrast, the legal cannabis sector thrives primarily in states that have adopted progressive legalization policies for medical and recreational use. Both markets hold transformative potential; however, it’s important to recognize the unique challenges and advantages each faces.

Cultural Perceptions: Changing Attitudes

Consumer education plays a pivotal role in shaping perceptions about hemp and cannabis. With increasing advocacy and awareness campaigns, attitudes towards both products are evolving. Understanding these cultural shifts helps inform where public interest may trend, possibly guiding future investment opportunities.

What's Next: Future Trends and Insights

The future of hemp and legal cannabis hinges on regulatory decisions and market readiness. As scientists explore the benefits of both, consumers will benefit from better quality products sourced sustainably. Advocating for informed choices and moderate regulation will be essential in maximizing the potential of both hemp and legal cannabis.

To keep up with the latest developments and trends in this competitive landscape, be proactive in exploring local dispensaries and cannabis education resources.

culture

2 Views

0 Comments

Write A Comment

Please complete the captcha to submit your comment.

Related Posts All Posts

Melt-to-Make Patented Gummy Base Technology Supports Scalable Cannabis Edibles Manufacturing

FOR IMMEDIATE RELEASE Cannabis / Nutraceuticals / Manufacturing / Patent / Gummies / Growth / Scaling “Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president at Melt-to-Make. NORTHAMPTON, Mass. — February 20, 2026 — As the global cannabis edibles market continues to expand, manufacturers are facing growing pressure to deliver compliant, consistent, and scalable products. According to Fortune Business Insights, the cannabis edibles market is projected to exceed $55 billion by 2034, reflecting sustained double-digit compound annual growth.The expanding market is increasing demand for manufacturing systems that reduce formulation variability while improving production efficiency. In response, many producers are adopting standardized formulation platforms to support reliable output across product lines, facilities, and geographic markets. Melt-to-Make has introduced a patented gelatin and pectin gummy base technology designed to address persistent bottlenecks in large-batch edible production. The company’s shelf-stable semi-finished gummy base can be heated and infused with active ingredients before molding, helping manufacturers simplify workflows while improving repeatability.By standardizing the gummy base, the Melt-to-Make system reduces common manufacturing challenges associated with traditional confectionery production, including inconsistent texture, lengthy research and development cycles, and batch failures during scale-up.“Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president of product development and research at Melt-to-Make. “When the formulation system itself is consistent and repeatable, manufacturers can concentrate on dosing precision and operational efficiency rather than troubleshooting structure and texture.” Traditional gummy production often requires specialized confectionery equipment and advanced formulation expertise, particularly when working with pectin in vegan and heat-stable applications. Melt-to-Make’s semi-finished gummy base is designed to integrate into existing production workflows, giving manufacturers a more standardized substrate for predictable results.As regulated cannabis markets in the United States and Europe continue implementing stricter quality control and labeling standards, consistency in edible production is becoming increasingly important for both regulatory compliance and long-term brand reliability.Standardized ingredient systems are emerging as a practical solution for achieving repeatable performance in expanding markets. Melt-to-Make currently serves clients in more than 15 countries and provides technical documentation, formulation tools, and production support for manufacturers implementing the technology.To learn more, visit www.melt-to-make.com. About Melt-to-Make™ Founded in 2018 in Northampton, Massachusetts, by Sarah McLaughlin, Jake Goodyear, and Tim Van Epps, Melt-to-Make™ specializes in innovative gummy base systems designed to simplify large-batch gummy manufacturing. By offering professionally formulated gelatin and pectin bases that are approximately 90% complete, the company helps manufacturers produce gummies faster, more efficiently, and with greater consistency.Melt-to-Make™ is committed to using all-natural ingredients and colors while supporting a wide range of consumer preferences, including vegan, gluten-free, and non-GMO options. The company serves more than 1,000 B2B customers across the United States and in 15 countries, offering comprehensive support that includes equipment lists, training videos, custom formulations, and on-site technical assistance.For more information, visit www.melt-to-make.com or call 1-800-241-0341.Media ContactProven Media Kim Prince Phone: 480-221-7995 Email: kim@provenmedia.com

The Green Wave: Medical Cannabis Takes Root in 40 States

Update Understanding the Shift Towards Medical Cannabis A recent report from the National Conference of State Legislatures (NCSL) establishes that as of June 2025, a remarkable 40 states, three territories, and Washington, D.C., now permit the medical use of cannabis. This represents a significant shift within U.S. policy, highlighting the changing landscape of healthcare driven by patient needs and scientific findings. For cultivation experts, the implications of this green wave are profound, offering new opportunities to understand and engage with a diverse market. The Drivers Behind Cannabis Legalization Why has the acceptance of medical cannabis surged? Three interconnected factors play a crucial role: Patient Advocacy: Real-life testimonials from patients who have found relief from ailments such as chronic pain and anxiety have been central to this movement. Personal stories resonate widely, creating a groundswell of support amongst the general public. Scientific Research: Despite the challenges that federal restrictions place on cannabis research, the growing body of evidence supporting the therapeutic benefits of cannabinoids like THC and CBD is undeniable. Cultivators must stay informed about these studies to optimize their practices for various medical applications. Shifting Public Opinion: Understanding cannabis as a legitimate medical treatment rather than a mere recreational drug has become increasingly prevalent. This shift opens avenues for more robust education around its usage across various conditions, influencing not just patients but also healthcare practices. Diversifying Cannabis Products Today's cannabis market is diverse, moving beyond traditional smoked products to include a wide range of formulations catering to various consumer needs. For cultivation experts, this diversification presents both challenges and opportunities: Edibles: From gummies to chocolates, edibles offer smoke-free consumption and are growing in popularity among medical users seeking discretion. Tinctures and Oils: These products allow for precise dosing, appealing to patients who prefer measurement over guesswork. Topicals: Creams and balms are ideal for localized relief, ensuring that users can target specific areas without psychoactive effects. Vaporization: Known for quick onset, vaping remains one of the most user-friendly methods for medical cannabis consumption. Pills: The move towards pill form standardizes doses and effects, providing a familiar method to more users. The Future of Cannabis Legislation While states lead the charge in cannabis legalization, a significant paradox remains: cannabis is still illegal at the federal level, classified as a Schedule I substance. This inconsistency impacts not only consumer access but also research and market operations. Cultivation experts must navigate this unique legal environment and advocate for sensible reforms that reflect the realities of the marketplace. The trend hints at possible federal reforms on the horizon, which could dramatically alter the industry landscape. Conclusion: Embracing the Green Wave As the medical cannabis landscape evolves, it presents a dynamic environment for cultivation experts and consumers alike. The focus on patient needs, coupled with scientific advocacy, suggests a continued push toward integration within healthcare systems. The growing understanding of cannabis not only as a trend but as a legitimate aspect of health can no longer be ignored, driving cultivation experts to adapt and prepare for an industry that values quality, research, and patient advocacy.

Cannabis Businesses Face Long Road Ahead with 280E Tax Relief Concerns

Update The Ongoing Burden of 280E on Cannabis BusinessesThe cannabis industry is celebrating an important milestone with the potential rescheduling of cannabis from a Schedule I to a Schedule III substance. Yet, despite this significant change in federal perception, cannabis businesses should remain cautious about potential tax relief from the burdensome 280E tax code. It’s easy to get caught up in the excitement, but tax experts advise patience, indicating that immediate relief might not arrive just yet.Understanding the 280E Tax CodeSection 280E of the Internal Revenue Code is a frustrating reality for many cannabis businesses. It prohibits them from deducting business expenses related to the trafficking of controlled substances listed in Schedules I and II, including cannabis. This means that, unlike traditional retail businesses that can deduct the costs of rent, utilities, and salaries, cannabis businesses are taxed on their gross income. This leads to effective tax rates that can soar above 50%, placing an unfair financial burden on a burgeoning industry.What Could Change with Rescheduling?The proposed shift to Schedule III could signal a significant change, suggesting that the stringent restrictions tied to 280E might start to loosen. Schedule III substances are recognized for having medical uses and a lower potential for abuse. If cannabis were to move from Schedule I, theoretically 280E's application should weaken. However, the timeline for this process is murky and extends beyond mere rescheduling.Adapting Until the ChangeFor now, cannabis businesses must adapt to the existing framework. Experts recommend exploring different strategies to mitigate the overwhelming tax burden imposed by 280E. Options like implementing Employee Stock Ownership Plans (ESOPs) can effectively remove some income from taxable streams, allowing businesses to navigate the tax landscape more effectively. Alternatively, Section 471(c) provides pathways for certain small cannabis businesses to adjust their inventory accounting, enabling them to include otherwise disqualified costs in their Cost of Goods Sold (COGS).The Road Ahead: Why Patience is KeyDespite the positive outlook, cannabis businesses need to prepare for continued complications surrounding their tax obligations. While the eventual rescheduling heralds the potential for relief, it might take years before those changes impact tax filings effectively. This is especially true if the IRS requires time to implement adjustments and for tax guidance to be updated accordingly.Final Thoughts: A Balanced Perspective on 280E ReliefIn the grand scheme, rescheduling cannabis represents a paradigm shift, fostering a more favorable regulatory environment. However, it’s vital for those in the cannabis industry—cultivators, dispensary owners, and industry stakeholders—to maintain cautious optimism about immediate financial relief. The journey toward tax equity is ongoing, and with long-term strategies and expert guidance, cannabis businesses can navigate the current tax hurdles while paving the way for a more equitable future.

Hemp vs. Legal Cannabis: Who Will Come Out on Top?

Understanding the Battle: Hemp vs. Legal Cannabis

Legal Frameworks: A Complex Terrain

The Market Dynamics: Who's Winning?

Cultural Perceptions: Changing Attitudes

What's Next: Future Trends and Insights

Terms of Service

Privacy Policy

Core Modal Title